Suppr超能文献

肌萎缩侧索硬化症患者的日间咬嘴通气和夜间无创通气与气管切开有创通气的比较。

Diurnal mouthpiece ventilation and nocturnal non-invasive ventilation versus tracheostomy invasive ventilation in patients with amyotrophic lateral sclerosis.

机构信息

Unit of Respiratory Diseases, General Hospital, Sestri Levante, Genoa, Italy -

Unit of Physical Medicine and Rehabilitation, General Hospital, Sestri Levante, Genoa, Italy.

出版信息

Panminerva Med. 2020 Mar;62(1):19-25. doi: 10.23736/S0031-0808.19.03644-9. Epub 2019 May 30.

Abstract

BACKGROUND

Respiratory disorders are a major cause of morbidity and mortality in amyotrophic lateral sclerosis (ALS). Current guidelines suggest the provision of noninvasive ventilation (NIV) for symptomatic hypoventilation in patients with ALS. Inspite of these results the proportion of ALS patients on tracheostomy invasive ventilation (TIV) is relatively high.

METHODS

Thirty-two patients were included in the study: 16 patients were treated with nocturnal NIV associated with diurnal mouthpiece ventilation (MPV) and 16 with TIV .The primary endpoint of the study was to evaluate survival in the two groups. Secondary endpoints were to evaluate differences in the two populations in terms of clinical outcomes and quality of life (HRQoL).

RESULTS

Cox analysis survival data shows no statically difference in the hazard function of the two groups. The comparison between the two groups showed a significant improvement in the average value of gas indices (paO2, paCO2) in the group treated with TIV in comparison to the group treated with MPV/NIV. Conversely, the evaluation of the questionnaires on HRQoL showed a higher score in patients treated with MPV/NIV compared to those treated with TIV.

CONCLUSIONS

Ventilatory treatment with MPV and TIV did not demonstrate significant differences in survival. Patients treated with MPV reported a better HRQoL, although TIV group showed higher ventilatory parameters improvement than MPV group.

摘要

背景

呼吸障碍是肌萎缩侧索硬化症(ALS)患者发病率和死亡率的主要原因。目前的指南建议对有症状性低通气的 ALS 患者提供无创通气(NIV)。尽管有这些结果,但接受气管切开术有创通气(TIV)的 ALS 患者比例相对较高。

方法

本研究共纳入 32 例患者:16 例患者接受夜间 NIV 联合日间面罩通气(MPV)治疗,16 例患者接受 TIV 治疗。研究的主要终点是评估两组患者的生存率。次要终点是评估两组患者在临床结局和生活质量(HRQoL)方面的差异。

结果

Cox 分析生存数据显示两组危险函数无统计学差异。两组比较显示,与接受 MPV/NIV 治疗的患者相比,接受 TIV 治疗的患者的气体指数(paO2、paCO2)的平均值有显著改善。相反,对 HRQoL 问卷的评估显示,与接受 TIV 治疗的患者相比,接受 MPV/NIV 治疗的患者的评分更高。

结论

接受 MPV 和 TIV 通气治疗的患者在生存率方面没有显著差异。接受 MPV 治疗的患者报告的 HRQoL 更好,尽管 TIV 组的通气参数改善高于 MPV 组。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验